Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02717325 · ClinicalTrials.gov registry record · NA

18842 - Sun Protection Factor Assay

A NA study of Sunscreening Agent, sponsored by Bayer.

Completed
Registry status
NA
Development phase
10
Enrollment target
1
Study location

NCT02717325: Completed NA study of Sunscreening Agent, sponsored by Bayer.

NCT02717325 is a NA study of Sunscreening Agent that has completed, run by Bayer. The registered enrollment target is 10 participants, below the 23-participant average among 7 other Sunscreening Agent trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02717325, a NA study of Sunscreening Agent, has completed, sponsored by Bayer.

COMPLETED
Registry status
NA
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

To evaluate the Sun Protection Factor (SPF) efficacy on human skin.

Conditions Studied

Interventions

  • DRUG Coppertone (BAY987517)

Study Locations (1)

New Jersey

  • - Union

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2016-03-16
Est. Completion 2016-03-31
Phase NA
Bayer

591 total trials

What the finished NCT02717325 record still lists

NCT02717325 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 23-participant average among 7 other Sunscreening Agent trials with a reported enrollment target (57% lower).

The record links to 1 condition, with Sunscreening Agent appearing as the primary indexed condition, and to 1 intervention - of which Coppertone (BAY987517) is the first listed.

NCT02717325 reports a single indexed study location in New Jersey.

Frequently Asked Questions

What is clinical trial NCT02717325 about?

NCT02717325 is a clinical study titled "18842 - Sun Protection Factor Assay". To evaluate the Sun Protection Factor (SPF) efficacy on human skin.

What is the current status of trial NCT02717325?

This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2016-03-16. Estimated completion is 2016-03-31.

What conditions does trial NCT02717325 study?

This clinical trial studies the following conditions: Sunscreening Agent.

What interventions are being tested in trial NCT02717325?

The interventions under investigation include: Coppertone (BAY987517) (DRUG).

Who is sponsoring clinical trial NCT02717325?

This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02717325 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sunscreening Agent

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02717325, the US trial registry maintained by the National Library of Medicine. NCT02717325 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.